enGene Holdings Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that enGene Holdings Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | ($117.30M) | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | ($55.14M) | Dec 22, 2025 |
| FY2024 | Oct 31, 2023 | ($99.92M) | Dec 19, 2024 |
| FY2023 | Oct 31, 2022 | ($24.46M) | Jan 29, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | ($123.17M) | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | ($62.30M) | Dec 22, 2025 |
| FY2024 | Oct 31, 2023 | ($26.06M) | Dec 19, 2024 |
| FY2023 | Oct 31, 2022 | ($19.43M) | Jan 29, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $94.48M | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | $38.32M | Dec 22, 2025 |
| FY2024 | Oct 31, 2023 | $16.46M | Dec 19, 2024 |
| FY2023 | Oct 31, 2022 | $15.47M | Jan 29, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | ($99.24M) | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | ($48.28M) | Dec 22, 2025 |
| FY2024 | Oct 31, 2023 | ($24.74M) | Dec 19, 2024 |
| FY2023 | Oct 31, 2022 | ($17.59M) | Jan 29, 2024 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $1.49M | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | $925.0K | Dec 22, 2025 |
| FY2024 | Oct 31, 2023 | $318.0K | Dec 19, 2024 |
| FY2023 | Oct 31, 2022 | $153.0K | Jan 29, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $221.47M | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | $311.17M | Dec 22, 2025 |
| FY2024 | Oct 31, 2023 | $86.96M | Dec 19, 2024 |
| FY2023 | Oct 31, 2022 | $23.91M | Jan 29, 2024 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $53.76M | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | $38.56M | Dec 22, 2025 |
| FY2024 | Oct 31, 2023 | $14.47M | Dec 19, 2024 |
| FY2023 | Oct 31, 2022 | $47.41M | Jan 29, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $167.71M | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | $272.61M | Dec 22, 2025 |
| FY2025 | Oct 31, 2023 | $72.49M | Dec 22, 2025 |
| FY2024 | Oct 31, 2022 | ($76.61M) | Dec 19, 2024 |
| FY2023 | Oct 31, 2021 | ($53.44M) | Jan 29, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | ($372.03M) | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | ($254.73M) | Dec 22, 2025 |
| FY2024 | Oct 31, 2023 | ($199.59M) | Dec 19, 2024 |
| FY2023 | Oct 31, 2022 | ($99.67M) | Jan 29, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $50.15M | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | $173.00M | Dec 22, 2025 |
| FY2024 | Oct 31, 2023 | $81.52M | Dec 19, 2024 |
| FY2023 | Oct 31, 2022 | $20.43M | Jan 29, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | 2 | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | 1 | Dec 22, 2025 |
| FY2024 | Oct 31, 2023 | 151 | Dec 19, 2024 |
| FY2023 | Oct 31, 2022 | 44 | Jan 29, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | 2 | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | 1 | Dec 22, 2025 |
| FY2024 | Oct 31, 2023 | 151 | Dec 19, 2024 |
| FY2023 | Oct 31, 2022 | 44 | Jan 29, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | 52.02M | Dec 22, 2025 |
| FY2025 | Oct 31, 2024 | 50.98M | Dec 22, 2025 |
| FY2024 | Oct 31, 2023 | 23.20M | Dec 19, 2024 |
| FY2023 | Oct 31, 2022 | 665,767 | Jan 29, 2024 |